Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.
Pharmacology, prescribing requirements, and patient preference are crucial factors in choosing opioid agonist treatments.
By Dennis Thompson HealthDay ReporterTUESDAY, Jan. 13, 2026 (HealthDay News) — Women with iron deficiency anemia caused by ...
Zacks Investment Research on MSN
INCY's phase III Monjuvi study meets key goals in first-line lymphoma
Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...
A single dose of intravenous (IV) iron dextran is the most cost-effective treatment for women with heavy menstrual bleeding ...
A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback